Israel
· Delayed Price · Currency is ILS · Price in ILA Oramed Pharmaceuticals Statistics
Total Valuation
TLV:ORMP has a market cap or net worth of ILS 340.59 million. The enterprise value is -175.88 million.
| Market Cap | 340.59M |
| Enterprise Value | -175.88M |
Important Dates
The next estimated earnings date is Friday, May 9, 2025.
| Earnings Date | May 9, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.65% |
| Shares Change (QoQ) | -0.56% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 32.47M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 0.64 |
| P/TBV Ratio | 0.64 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 2.53 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 5.73 |
Financial Position
The company has a current ratio of 25.19, with a Debt / Equity ratio of 0.00.
| Current Ratio | 25.19 |
| Quick Ratio | 24.97 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.04 |
| Interest Coverage | -14.98 |
Financial Efficiency
Return on equity (ROE) is -12.39% and return on invested capital (ROIC) is -4.43%.
| Return on Equity (ROE) | -12.39% |
| Return on Assets (ROA) | -4.25% |
| Return on Invested Capital (ROIC) | -4.43% |
| Return on Capital Employed (ROCE) | -8.54% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -17.36M |
| Employee Count | 4 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -1.94% in the last 52 weeks. The beta is 1.49, so TLV:ORMP's price volatility has been higher than the market average.
| Beta (5Y) | 1.49 |
| 52-Week Price Change | -1.94% |
| 50-Day Moving Average | 827.46 |
| 200-Day Moving Average | 860.00 |
| Relative Strength Index (RSI) | 54.49 |
| Average Volume (20 Days) | 7,227 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.69 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -46.55M |
| Pretax Income | -57.99M |
| Net Income | -69.42M |
| EBITDA | -45.85M |
| EBIT | -46.55M |
| Earnings Per Share (EPS) | -1.75 |
Balance Sheet
The company has 516.95 million in cash and 1.35 million in debt, giving a net cash position of 515.60 million.
| Cash & Cash Equivalents | 516.95M |
| Total Debt | 1.35M |
| Net Cash | 515.60M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 529.40M |
| Book Value Per Share | 13.35 |
| Working Capital | 500.95M |
Cash Flow
In the last 12 months, operating cash flow was -30.64 million and capital expenditures -65,561, giving a free cash flow of -30.70 million.
| Operating Cash Flow | -30.64M |
| Capital Expenditures | -65,561 |
| Free Cash Flow | -30.70M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TLV:ORMP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.65% |
| Shareholder Yield | -0.65% |
| Earnings Yield | -20.38% |
| FCF Yield | -9.02% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |